StreetInsider.com News Articles

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

FDA clears Implantica's RefluxStop implant for U.S. market

Thu, 20 Aug 2026 23:32:22 -0400

Implantica AG received Premarket Approval from the U.S. Food and Drug Administration for its RefluxStop device, a GERD treatment implant, the company announced Aug. 20, 2026.

The approval follows the FDA's review of the PMA application, which included five-year clinical safety and effectiveness data. RefluxStop is designed to treat gastroesophageal reflux disease by restoring the natural position of the gastroesophageal junction without encircling or applying pressure to the esophagus.

Implantica said its initial U.S. rollout will target selected surgical centers and reflux surgeons, with commercial adoption expected to build gradually as physician training and site activation are completed.

The company, listed on Nasdaq